PMGC Holdings旗下Northstrive保留EL-32人权授权 Modulant获独家动物健康许可

美股速递
Apr 13

PMGC Holdings宣布,其子公司Northstrive将保留EL-32化合物在人类医疗领域的全球开发与商业化权利。与此同时,合作企业Modulant获得了该化合物在动物健康领域的独家授权许可。

此次授权划分明确了双方在EL-32应用领域的商业边界。Northstrive将继续推进EL-32在人类疾病治疗方面的临床研究,而Modulant将专注于开发针对伴侣动物和畜牧动物的新型治疗方案。

这一战略安排有助于双方集中资源深耕各自专业领域,为EL-32的商业化路径提供更明确的发展方向。化合物授权范围的细分也体现了精准医疗时代下知识产权管理的精细化趋势。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10